Skip to main content
NANOVEU LIMITED logo

NANOVEU LIMITED — Investor Relations & Filings

Ticker · NVU ISIN · AU0000024796 LEI · 5299003PDOQ5DPU98119 ASX Manufacturing
Open in API
Filings indexed 627 across all filing types
Latest filing 2021-08-22 Capital/Financing Update
Country AU Australia
Listing ASX NVU

About NANOVEU LIMITED

https://nanoveu.com/

Nanoveu Limited specializes in the development of advanced materials and digital imaging solutions through nanotechnology. The company’s product portfolio includes EyeFly3D, a specialized film and software platform that enables glasses-free 3D visualization on mobile devices. Its Nanoshield product line features antimicrobial coatings and films that utilize copper ions to eliminate pathogens on frequently touched surfaces. Furthermore, the company is advancing EyeFyx technology, which aims to provide vision correction for individuals with presbyopia by manipulating digital screen output. Nanoveu focuses on integrating proprietary thin-film coatings with sophisticated algorithms to enhance display functionality and provide protective surface treatments across various consumer and commercial applications.

Recent filings

Filing Released Lang Actions
Nanoveu Continues Global Expansion with Antiviral Face Masks 3 pages 629.3KB
Capital/Financing Update Classification · 95% confidence The document is an ASX release dated 23 August 2021 from Nanoveu Limited announcing a new order and expansion of their antiviral face mask product line. It contains no financial statements, no detailed financial performance data, no regulatory certifications, or voting results. It is a corporate announcement about a business development and product expansion, typical of a Capital/Financing Update or general corporate update. The document is not a full financial report, audit, earnings release, or management discussion. It is not a report publication announcement since it contains substantive content about the business activity. Therefore, the best fitting category is Capital/Financing Update (CAP).
2021-08-22 English
ANZ distributor signs agreement with Linfox Armaguard 2 pages 114.6KB
Regulatory Filings Classification · 95% confidence The document is an ASX release announcing a new distribution agreement between Nanoveu Limited's distributor and Linfox Armaguard. It discusses the partnership and product rollout plans but explicitly states there is no current financial impact. The document is short (2874 characters) and is an announcement of a business development rather than a financial report or regulatory filing. There is no indication of financial statements, management discussion, or regulatory compliance content. Therefore, it fits best as a general regulatory announcement about business activities, which falls under Regulatory Filings (RNS).
2021-08-10 English
Response to ASX Aware Letter 6 pages 360.2KB
Regulatory Filings Classification · 95% confidence The document is a letter from Nanoveu Limited responding to an ASX Compliance Pty Ltd query regarding a recent announcement about successful testing results of their Nanoshield antiviral technology against SARS-CoV-2. The letter addresses questions about the timing and disclosure of material information under ASX Listing Rules 3.1 and 3.1A, confirming compliance with continuous disclosure obligations. The content is a regulatory compliance correspondence related to disclosure of price-sensitive information and trading rules, not a financial report, earnings release, or other report type. It is a formal regulatory filing responding to a market regulator's inquiry, fitting the definition of a Regulatory Filing (RNS). The document length is about 11,903 characters, but it is primarily a letter and not a report or announcement of a report publication. Therefore, the appropriate classification is Regulatory Filings (RNS).
2021-08-01 English
Quarterly Activities/Appendix 4C Cash Flow Report 8 pages 1.2MB
Interim / Quarterly Report Classification · 100% confidence The document is an ASX release titled 'Quarterly Activities Report and Appendix 4C for the Quarter Ended 30 June 2021'. It includes detailed financial data such as cash flow statements, expenditure, payments to related parties, and financing facilities. The presence of the Appendix 4C, which is a quarterly cash flow report required by ASX Listing Rule 4.7B, confirms this is a quarterly report. The document contains substantive financial data and analysis for a period shorter than a full fiscal year (quarterly). Therefore, it fits the definition of an Interim / Quarterly Report (IR). Q2 2021
2021-07-28 English
Nestle Research validates Nanoshield with SARS-CoV-2 testing 27 pages 1.3MB
Regulatory Filings Classification · 95% confidence The document is an ASX release from Nanoveu Limited dated 28 July 2021, announcing the validation of their Nanoshield product's antiviral efficacy against SARS-CoV-2 by Nestle Research. The text includes detailed scientific study results, testing protocols, and commentary from the CEO. It is a corporate announcement of research findings and product validation rather than a financial report or regulatory filing. The document is lengthy (15,000 characters) and contains substantive content about product efficacy and scientific validation, but it is not a financial report, earnings release, or management discussion. It is an official company announcement related to product validation and scientific research results, which fits best under Regulatory Filings (RNS) as it does not match other specific categories like earnings, capital updates, or governance. It is not a report publication announcement since it contains the full announcement and detailed study summary, not just a notice of report availability.
2021-07-27 English
Notification of cessation of securities - NVU 4 pages 24.3KB
Regulatory Filings Classification · 95% confidence The document is titled 'Notification of cessation of +securities' and details the lapse of performance rights securities for Nanoveu Limited. It provides specific information about the securities that have ceased, the reason for cessation, and the updated issued capital following these changes. There are no financial statements, earnings data, or management commentary. The document is an official announcement regarding changes in the company's securities, specifically the cessation of certain securities. This fits the category of Regulatory Filings (RNS) as it is a regulatory announcement about securities status changes that does not fit into more specific categories like capital changes or director dealings.
2021-07-07 English

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.